2022-08-19至2022-08-20 南京
导航

已确认嘉宾Confirmed Guests

胡适 教授

第二军医大学基础医学部

胡适 教授

第二军医大学基础医学部

胡适,男,第二军医大学基础医学院教授,硕士生导师。研究方向为抗体药物工程和新型细胞治疗技术。现主持国家自然科学基金新型冠状病毒专项、面上项目、重大新药创制子课题等十余项各类科研项目。近五年内以通讯作者在Science Translational Medicine,Nature Communications、Clinical Cancer Research等国际刊物上发表SCI论文二十余篇,申请中国专利19项,PCT专利8项。主要研究方向包括新型抗体工程技术和细胞治疗技术的应用研究。


 

代表论著

(1) Shi Hu*, Wenyan Fu, Tian Li, Ying Tang, Qingning Yuan, FeifeiWang, Gaojian Lv, Yuanyuan Lv, Xiaoyan Fan, Sheng Zhang, Ruobing Jin, Yafeng Shen, Fangxing Lin, Xuting Ye, Yongji Yang, and Changhai Lei*. Antagonism of EGFR and Notch Limits Acquired Resistance to EGFR Inhibitors and Radiation by Decreasing Tumor-Initiating Cell Frequency. Science Translation Medicine, 2017. 9(380): p. eaag0339.

(2) Shi Hu*, Wenyan Fu, Weihao Xu, Yang Yang, Melissa Cruz, Sandra D Berezov, Daniel Jorissen, Hiroaki Takeda, and Wangdong Zhu*, Four-in-one antibodies have superior cancer inhibitory activity against EGFR, HER2, HER3, and VEGF through disruption of HER/MET crosstalk. Cancer research, 2015. 75(1): p. 159-170.

(3) Shi Hu*, Haibin Dai, Tian Li, Ying Tang, Wenyan Fu, Qingning Yuan, FeifeiWang, Gaojian Lv, Yuanyuan Lv, Xiaoyan Fan, Sheng Zhang, Ruobing Jin, Yafeng Shen, Fangxing Lin, Xuting Ye, Min Ding, Yongji Yang, and Changhai Lei*. Broad RTK-targeted therapy overcomes molecular heterogeneity-driven resistance to cetuximab via vectored immunoprophylaxis in colorectal cancer. Cancer Letters, 2016, 382(1): 32-43.

(4) Shi Hu, Shuaiyi Liang, Huaizu Guo, Dapeng Zhang, Hui Li, Xiaoze Wang, Weili Yang, Weizhu Qian, Sheng Hou, Hao Wang, Yajun Guo*, and Zhiyong Lou*, Comparison of the Inhibition Mechanisms of Adalimumab and Infliximab in Treating Tumor Necrosis Factor α-Associated Diseases from a Molecular View. Journal of Biological Chemistry, 2013. 288(38): p. 27059-27067.


邀请函

下载邀请函
×
留下姓名电话和邮箱,邀请函直接发送到邮箱
*姓名:
* 电话:
* Email: